FDA 执法报告 D-0051-2027 记录辉瑞 Levoxyl 左甲状腺素钠片 175 mcg 批号 24W07 因稳定性试验效价不合格的 II 类召回
FDA drug enforcement D-0051-2027: Pfizer — Subpotent Drug: confirmed out-of-specification (OOS) assay during stability testing.
FDA 执法报告 D-0051-2027 记录辉瑞 Levoxyl(左甲状腺素钠片,USP)175 mcg 批号 24W07 因稳定性试验中确认效价 OOS 被列为 II 类召回。
该记录给出左甲状腺素钠片因稳定性试验效价不合格被列为 II 类召回的批号与分销范围,可作稳定性 OOS 讨论的背景事实。
FDA 药品召回执法报告 — D-0051-2027
报告发布日期:2026-10-28。这是执法报告日期,不是召回启动日期。
范围:一条已分类的药品召回记录;event_id 可能归组多个产品。没有召回编号的未分类记录不在本数据流范围内。本记录不是新闻稿,也不是新的执法认定。
openFDA 数据集每周更新。报告状态不是实时召回状态,不得用于跟踪召回生命周期。以下其他日期保留其各自名称所表示的含义。
完整的官方产品记录(包括 openFDA 统一标识符):
{
"address_1": "66 Hudson Blvd",
"address_2": "",
"center_classification_date": "20261016",
"city": "Manhattan",
"classification": "Class II",
"code_info": "Lot # 24W07, Exp: 11/30/2026",
"country": "United States",
"distribution_pattern": "US Nationwide and Puerto Rico",
"event_id": "99963",
"initial_firm_notification": "Letter",
"more_code_info": "",
"openfda": {
"application_number": [
"NDA021301"
],
"brand_name": [
"LEVOXYL"
],
"generic_name": [
"LEVOTHYROXINE SODIUM"
],
"is_original_packager": [
true
],
"manufacturer_name": [
"Pfizer Laboratories Div Pfizer Inc"
],
"package_ndc": [
"60793-850-10",
"60793-850-01",
"60793-851-10",
"60793-851-01",
"60793-852-10",
"60793-852-01",
"60793-853-10",
"60793-853-01",
"60793-854-10",
"60793-854-01",
"60793-855-10",
"60793-855-01",
"60793-856-10",
"60793-856-01",
"60793-857-10",
"60793-857-01",
"60793-858-10",
"60793-858-01",
"60793-859-10",
"60793-859-01",
"60793-860-10",
"60793-860-01"
],
"product_ndc": [
"60793-850",
"60793-851",
"60793-852",
"60793-853",
"60793-854",
"60793-855",
"60793-856",
"60793-857",
"60793-858",
"60793-859",
"60793-860"
],
"product_type": [
"HUMAN PRESCRIPTION DRUG"
],
"route": [
"ORAL"
],
"rxcui": [
"892246",
"892251",
"966157",
"966164",
"966170",
"966175",
"966184",
"966190",
"966194",
"966200",
"966204",
"966211",
"966220",
"966221",
"966222",
"966224",
"966225",
"966248",
"966249",
"966253",
"966270",
"966283"
],
"spl_id": [
"8ce3c272-807b-4a86-aa58-034013814264"
],
"spl_set_id": [
"758588c3-c63e-491b-0aa2-4f50d80cb174"
],
"substance_name": [
"LEVOTHYROXINE SODIUM"
],
"unii": [
"9J765S329G"
],
"upc": [
"0360793858012",
"0360793855011",
"0360793852010",
"0360793860015",
"0360793850016",
"0360793853017",
"0360793854014",
"0360793857015",
"0360793859019",
"0360793856018",
"0360793851013"
]
},
"postal_code": "10001-2189",
"product_description": "Levoxyl(左甲状腺素钠片,USP),片剂,175 mcg,1000 片/瓶,处方药,由 Pfizer Inc. 分销,地址 New York, NY 10017,奥地利制造。NDC 60793-859-10",
"product_quantity": "134 瓶(1000 片/瓶)",
"product_type": "Drugs",
"reason_for_recall": "含量不足药品:稳定性试验中确认含量测定结果不符合标准(OOS)。",
"recall_initiation_date": "20260929",
"recall_number": "D-0051-2027",
"recalling_firm": "Pfizer",
"report_date": "20261028",
"state": "NY",
"status": "Ongoing",
"voluntary_mandated": "Voluntary: Firm initiated"
}
来源:openFDA 已分级药品召回执法报告 · api.fda.gov